Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Socié, Gérard  [Clear All Filters]
2023
Fein JAlexander, Shouval R, Galimard J-E, Labopin M, Socié G, Finke J, Cornelissen JJ, Malladi R, Itälä-Remes M, Chevallier P, et al. Comorbidities in recipients of low transplant conditioning intensity regimens for acute myeloid leukemia: an ALWP EBMT study. Blood Adv. 2023.
Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani MAl, Lioure B, et al. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.
Villemonteix J, Allain V, Verstraete E, Jorge-Cordeiro D, Socié G, Xhaard A, Feray C, Caillat-Zucman S. HLA-DP diversity is associated with improved response to SARS-Cov-2 vaccine in hematopoietic stem cell transplant recipients. iScience. 2023;26(5):106763.
Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.
Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JYves, et al. A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023.
Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JHenri, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Hamed RAl, Ngoya M, Galimard J-E, Sengeloev H, Gedde-Dahl T, Kulagin A, Platzbecker U, Yakoub-Agha I, Byrne JL, Valerius T, et al. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study. Cancer. 2023.
2022
Xhaard A, Villate A, Hamane S, Michonneau D, Menotti J, Robin M, de Fontbrune FSicre, Dhedin N, de la Tour RPeffault, Socié G, et al. A 10-year retrospective analysis of Toxoplasma gondii qPCR screening in allogeneic hematopoietic stem cell transplantation recipients. Bone Marrow Transplant. 2022.
Buxbaum NProkopenko, Socié G, Hill GR, MacDonald KPa, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, et al. Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CPinho, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJurado, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022;9(1):e14-e25.
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, et al. Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.
Dubouchet L, Todorov H, Seurinck R, Vallet N, Van Gassen S, Corneau A, Blanc C, Zouali H, Boland A, Deleuze J-F, et al. Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Sci Transl Med. 2022;14(633):eabg3083.
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
2021
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
Qayed M, Michonneau D, Socié G, Waller EK. Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47.
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
2020
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, Leblond V, Chevallier P, Socié G, Araujo MColorado, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European. Am J Hematol. 2020.
Paviglianiti A, Labopin M, Blaise D, Socié G, Bulabois CEric, Lioure B, Ceballos P, Blau IWolfgang, Guillerm G, Maertens J, et al. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplant. 2020.
Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, Potter M, Malladi R, Byrne J, Schouten H, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2020.
Bondeelle L, Chevret S, Hurabielle C, Samy L, Goletto T, Costantini A, de Fontbrune FSicre, Michonneau D, Socié G, Tazi A, et al. Effect of Ruxolitinib on lung function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel M-J, Le Goff J, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 2020;4(9):1824-1832.
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Giannoni L, Morin F, Robin M, Peyneau M, Schlageter MHélène, Desmier D, Pagliuca S, Del Galy ASutra, de Fontbrune FSicre, Xhaard A, et al. Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2020.
Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, Fortin G, Meslin P-A, Yakoub-Agha I, Sujobert P, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.

Pages